A Thorough Look at the Different Surgical Choices for Ulcerative Colitis: How Various Medical Experts Work Together to Understand the Latest Treatments, New Possibilities, and What Might Come Next in the Field

Acute severe ulcerative colitis is a very serious ailment that involves hospital treatment and inhalation of powerful drugs such as intravenous steroids. About one-third of the individuals affected by this situation fail to show improvement with steroids alone, thus requiring other special medications. Infliximab or cyclosporine can be given to these patients as the means of treatment. The two drugs turn out to be equally effective, but doctors commonly choose infliximab because they find it more convenient and they have adequate experience of working with it. Nevertheless, should a patient have already been exposed to infliximab previously, then doctors are allowed to prescribe cyclosporine more frequently. When folks with severe ulcerative colitis do not respond positively to such therapies, the next step could be the surgical intervention, i.e., excision of the colon. The medical community is very active in looking for more ways of treating the condition that do not involve surgery. Previous studies have shown that medicines like Janus kinase inhibitors are of great help when applied together with steroids at the beginning or used as a single treatment, respectively, though their effectiveness still needs to be established through further research.

Ulcerative operation, bowel movement, Corticosteroid

1. Le Berre C, Honap S Peyrin- Biroulet L wrote about Ulcerative Colitis in the Lancet. This was published in 2023. The article is in volume 402 issue 10401 on pages 571 to 584. [Google Scholar] [Crossref]

2. Ng SC, Shi HY, Hamidi N and others did a study on Ulcerative Colitis. They looked at how common Ulcerative Colitiss around the world. This study was published in the Lancet in 2017. It is in volume 390 issue 10114 on pages 2769 to 2778. [Google Scholar] [Crossref]

3. Yamazaki M, Chung H, Xu Y and others looked at Ulcerative Colitis trends. They compared Ulcerative Colitis in Japan and the US. This was published in the International Journal of Colorectal Disease in 2023. [Google Scholar] [Crossref]

4. Voelker R wrote about what Ulcerative Colitiss. This was published in the Journal of the American Medical Association in 2024. [Google Scholar] [Crossref]

5. Liang Y, Li Y, Lee C and others wrote about Ulcerative Colitis treatment. They talked about using molecules to treat Ulcerative Colitis. This was published in Molecular Biomedicine in 2024. [Google Scholar] [Crossref]

6. Kaluzna A, Olczyk P, Komosinska- Vassev K, Hebelka H Lagerstrand KM looked at how the immune system affects Ulcerative Colitis. They wanted to know how the immune system helps Ulcerative Colitis start and get worse. This was published in the Journal of Clinical Medicine in 2022. [Google Scholar] [Crossref]

7. Swirkosz G, Szczygiel A, Logon K and others did a review of the microbiome. They looked at how the microbiome affects Ulcerative Colitis. This was published in Biomedicines in 2023. [Google Scholar] [Crossref]

8. Ananthakrishnan AN, Murad MH, Scott FI and others compared Ulcerative Colitis treatments. They wanted to know which treatments work best for moderate to Ulcerative Colitis. This was published in Gastroenterology in 2024. [Google Scholar] [Crossref]

9. Chang S, Murphy M Malter L reviewed the medicines used to treat Ulcerative Colitis. They looked at the medicines that're available to treat moderate to severe Ulcerative Colitis. This was published in the American Journal of Gastroenterology in 2024. [Google Scholar] [Crossref]

10. Dulai PS, Singh S Jairath V and others talked about using biologics to treat Ulcerative Colitis. They wanted to know how to use these medicines to treat Ulcerative Colitis. This was published in Gastroenterology in 2024. [Google Scholar] [Crossref]

11. Claytor, Faith JJ Jennifer D and others wrote about Fecal Microbiota Transplantation. They looked at using Fecal Microbiota Transplantation to treat Ulcerative Colitis. This was published in Clinical Gastroenterology and Hepatology in 2024. [Google Scholar] [Crossref]

12. Bulut Gökten D, Çabuk B, Solakoğlu T and others did a study on arthritis. They looked at how enteropathic arthritis affects people, with Ulcerative Colitis. This was published in the Egyptian Rheumatologist in 2024. [Google Scholar] [Crossref]

13. Wangchuk P, Yeshi K and Loukas A wrote about Ulcerative Colitis, which includes biomarkers, therapeutic targets and emerging treatments. They published this in Trends Pharmacol Sci in 2024. [Google Scholar] [Crossref]

14. Thoo L, Noti M and Krebs P talked about the barrier and how it works. They said it is like being at the interface of peace and war. This was published in Cell Death Dis in 2019. [Google Scholar] [Crossref]

15. Villanacci V, Del Sordo R, Lanzarotto F and others found that Claudin-2 is a marker for evaluating histological mucosal healing in inflammatory bowel diseases. They published this in Dig Liver Dis in 2024. [Google Scholar] [Crossref]

16. Saez A, Herrero-Fernandez B, Gomez-Bris R and others wrote about the pathophysiology of Inflammatory Bowel Disease and the innate immune system. This was published in Int J Mol Sci in 2023. [Google Scholar] [Crossref]

17. Wu Y and Shen J talked about extracellular traps in inflammatory bowel disease. They discussed pathways, biomarkers and promising therapies. This was published in Cytokine Growth Factor Rev in 2024. [Google Scholar] [Crossref]

18. Tyler CJ, Guzman M, Lundborg LR and others found that antibody secreting cells are dependent on integrin alpha4beta7/MAdCAM-1 for recruitment and control of the microbiota during chronic colitis. They published this in Mucosal Immunol in 2022. [Google Scholar] [Crossref]

19. Grames M, Breviario F Pintucci G and others found that interleukin-1 enhances plasminogen activator inhibitor activity in endothelial cells. This was published in Biochem Biophys Res Commun in 1986. [Google Scholar] [Crossref]

20. Sanchez-Munoz F, Dominguez-Lopez A and Yamamoto-Furusho JK wrote about the role of cytokines in bowel disease. They published this in World J Gastroenterol in 2008. [Google Scholar] [Crossref]

21. Nakase H, Sato N Mizuno N and others talked about the influence of cytokines on the pathology of Ulcerative Colitis. This was published in Autoimmun Rev in 2022. [Google Scholar] [Crossref]

22. Wan X, Zhang C, Lei P and others developed precision therapeutics for bowel disease. They used ROS- nanoparticles for targeted and multifunctional drug delivery. This was published in J Mater Chem B in 2025. [Google Scholar] [Crossref]

23. Guo J, Li L Cai Y and others developed probiotics and prebiotics therapy for Ulcerative Colitis. This therapy has gained a lot of attention. They published this in Cell Commun Signal in 2024. [Google Scholar] [Crossref]

24. Do KH, Ko SH, Kim KB and others compared the microbiome in patients with Ulcerative Colitis and healthy controls in Korea. This was published in Microorganisms in 2023. [Google Scholar] [Crossref]

25. Pandey H, Jain D, Tang DWT and others wrote about the gut microbiota, in the pathophysiology, diagnosis and therapeutics of bowel disease. They published this in Intest Res in 2024. [Google Scholar] [Crossref]

• Contributory Effect of Adenosine Triphosphate (ATP) To Male Infertility
• Standardization in Clinical Trials: Optimizing Biospecimen Collection, Preservation, and Export
• Prevalence of Extended Spectrum Beta-Lactamase Producing Klebsiella Pneumoniae and Escherichia Coli Among Clinical Isolates in Lautech Teaching Hospital, Ogbomoso, Oyo State, Nigeria
• In-Vivo and In-Silico Investigation of the Hepatoprotective Activity of Tetracarpidium Conophorum (African Walnut) In Mercury-Exposed Male Wistar Rats
• Activated Platelet-Rich Plasma Improves Locomotor Functional Recovery and Attenuates Glial Scars Formation in Spinal Cord Injury Rats